UPDATE 1-Valeant trumps Endo with increased bid for Salix Pharma

March 16 (Reuters) - Valeant Pharmaceuticals International Inc said it increased its offer for Salix Pharmaceuticals Inc to $10.96 billion in cash, topping Endo International Plc's bid of $10.93 billion in cash and stock for the bowel drug maker.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.